Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate Cancer

• Mutation mapping using the OncoMap and other genotyping techniques [ Time Frame: Baseline ] [ Designated as safety issue: No ]
  
• DNA genomic sequencing [ Time Frame: Baseline ] [ Designated as safety issue: No ]
  
• Gene expression profile using microarray assays [ Time Frame: Baseline ] [ Designated as safety issue: No ]
  

• Expression of androgen metabolic enzymes by quantitative real time-polymerase chain reaction [ Time Frame: Baseline ] [ Designated as safety issue: No ]
  
• Proteomic profile [ Time Frame: Baseline ] [ Designated as safety issue: No ]
  
• mRNA expression profile in plasma and tissue [ Time Frame: Baseline ] [ Designated as safety issue: No ]
  

PRIMARY OBJECTIVE:

I. Obtain tumor biopsies and matched blood samples from patients with localized and metastatic castration sensitive or castration resistant prostate cancer for: mutation mapping using OncoMap and other high throughput genotyping technologies; sequencing of tumor genomic deoxyribonucleic acid (DNA); global assessment of gene expression to generate hypotheses that can be tested in subsequent trials (by gene expression microarrays and/or complementary [c]DNA sequencing and/or micro-ribonucleic acid [RNA]/noncoding RNA analysis); profiling of genes involved in androgen metabolism; quantitating peptides, hormones and other locally-derived or systemic metabolites present in tumor tissues.

SECONDARY OBJECTIVES:

I. Determine whether levels of other androgen synthetic enzymes predict responses to agents targeting the androgen-AR signaling axis.

II. Determine whether intratumoral androgen levels are increased compared to serum levels, and whether they correlate with androgen synthetic enzyme levels and/or responses to therapy.

III. Determine whether time to progression on therapy correlates with androgen biosynthetic enzymes or hormone levels.

IV. Determine whether gene expression profiling can predict response and time to progression for chemotherapy or targeted agents.

V. Compare plasma expression profiles of microRNAs/noncoding RNAs to those of prostate cancer tissue and determine whether plasma microRNA/noncoding RNA signatures can predict response and time to progression for hormonal therapies, chemotherapy, and/or targeted agents.

OUTLINE:

Patients undergo collection of blood and tissue samples for analysis via mutation mapping, DNA sequencing, gene expression microarray, RNA analysis, and gene profiling.